Lack of benefit from PD-1/PD-L1 inhibitors in pancreatic cancer is thought to arise from multiple reasons such as lack of immune cell infiltration, their dysfunction, low mutational burden, immunosuppressive tumor microenvironment (TME), and dense stroma limiting drug perfusion [7, 8]. This evidence concerns the gene PDCD1 and pancreatic neoplasm.